Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Suppressed Fat Mobilization Due to PNPLA3 rs738409 -Associated Liver Damage in Heavy Drinkers: The Liver Damage Feedback Hypothesis.

Rausch V, Mueller S.

Adv Exp Med Biol. 2018;1032:153-172. doi: 10.1007/978-3-319-98788-0_12.

PMID:
30362098
2.

Primary liver injury and delayed resolution of liver stiffness after alcohol detoxification in heavy drinkers with the PNPLA3 variant I148M.

Rausch V, Peccerella T, Lackner C, Yagmur E, Seitz HK, Longerich T, Mueller S.

World J Hepatol. 2016 Dec 18;8(35):1547-1556. doi: 10.4254/wjh.v8.i35.1547.

3.

I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders.

Xia MF, Ling Y, Bian H, Lin HD, Yan HM, Chang XX, Li XM, Ma H, Wang D, Zhang LS, Wang SS, Wu BJ, He WY, Zhao NQ, Gao X.

Aliment Pharmacol Ther. 2016 Mar;43(5):631-42. doi: 10.1111/apt.13521. Epub 2016 Jan 13.

4.

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.

Donati B, Motta BM, Pingitore P, Meroni M, Pietrelli A, Alisi A, Petta S, Xing C, Dongiovanni P, del Menico B, Rametta R, Mancina RM, Badiali S, Fracanzani AL, Craxì A, Fargion S, Nobili V, Romeo S, Valenti L.

Hepatology. 2016 Mar;63(3):787-98. doi: 10.1002/hep.28370. Epub 2016 Jan 14.

PMID:
26605757
5.

A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population.

Verrijken A, Beckers S, Francque S, Hilden H, Caron S, Zegers D, Ruppert M, Hubens G, Van Marck E, Michielsen P, Staels B, Taskinen MR, Van Hul W, Van Gaal L.

Obesity (Silver Spring). 2013 Oct;21(10):2138-45. doi: 10.1002/oby.20366. Epub 2013 Jun 6.

6.

Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians.

Stickel F, Buch S, Lau K, Meyer zu Schwabedissen H, Berg T, Ridinger M, Rietschel M, Schafmayer C, Braun F, Hinrichsen H, Günther R, Arlt A, Seeger M, Müller S, Seitz HK, Soyka M, Lerch M, Lammert F, Sarrazin C, Kubitz R, Häussinger D, Hellerbrand C, Bröring D, Schreiber S, Kiefer F, Spanagel R, Mann K, Datz C, Krawczak M, Wodarz N, Völzke H, Hampe J.

Hepatology. 2011 Jan;53(1):86-95. doi: 10.1002/hep.24017. Epub 2010 Dec 7.

PMID:
21254164
7.

Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.

Stättermayer AF, Traussnigg S, Aigner E, Kienbacher C, Huber-Schönauer U, Steindl-Munda P, Stadlmayr A, Wrba F, Trauner M, Datz C, Ferenci P.

J Trace Elem Med Biol. 2017 Jan;39:100-107. doi: 10.1016/j.jtemb.2016.08.006. Epub 2016 Aug 20.

PMID:
27908400
8.

Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis.

Finkenstedt A, Auer C, Glodny B, Posch U, Steitzer H, Lanzer G, Pratschke J, Biebl M, Steurer M, Graziadei I, Vogel W, Zoller H.

Clin Gastroenterol Hepatol. 2013 Dec;11(12):1667-72. doi: 10.1016/j.cgh.2013.06.025. Epub 2013 Jul 18.

PMID:
23872669
9.

The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).

Arslanow A, Stokes CS, Weber SN, Grünhage F, Lammert F, Krawczyk M.

Liver Int. 2016 Mar;36(3):418-26. doi: 10.1111/liv.12937. Epub 2015 Oct 3.

PMID:
26264356
10.

PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.

Krawczyk M, Jiménez-Agüero R, Alustiza JM, Emparanza JI, Perugorria MJ, Bujanda L, Lammert F, Banales JM.

Surg Obes Relat Dis. 2016 Dec;12(10):1838-1846. doi: 10.1016/j.soard.2016.06.004. Epub 2016 Jul 1.

PMID:
27576208
11.

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, Day CP, Daly AK, Reeves HL, Anstee QM.

J Hepatol. 2014 Jul;61(1):75-81. doi: 10.1016/j.jhep.2014.02.030. Epub 2014 Mar 6.

PMID:
24607626
12.

Noninvasive characterization of graft steatosis after liver transplantation.

Karlas T, Kollmeier J, Böhm S, Müller J, Kovacs P, Tröltzsch M, Weimann A, Bartels M, Rosendahl J, Mössner J, Berg T, Keim V, Wiegand J.

Scand J Gastroenterol. 2015 Feb;50(2):224-32. doi: 10.3109/00365521.2014.983156. Epub 2014 Nov 27.

PMID:
25429378
13.

Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease.

Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, Chayama K, Nakajima A, Nakao K, Sekine A.

BMC Med Genet. 2010 Dec 22;11:172. doi: 10.1186/1471-2350-11-172.

14.

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.

Scheiner B, Mandorfer M, Schwabl P, Payer BA, Bucsics T, Bota S, Aichelburg MC, Grabmeier-Pfistershammer K, Stättermayer A, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T.

PLoS One. 2015 Nov 23;10(11):e0143429. doi: 10.1371/journal.pone.0143429. eCollection 2015.

15.

Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.

Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, Di Marco V, Cammà C, Mensi L, Dongiovanni P, Valenti L, Craxì A, Fargion S.

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.

PMID:
28554682
16.

The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.

Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani L, Motta BM, Canavesi E, Fracanzani AL, Mozzi E, Roviaro G, Magni P, Fargion S.

BMC Gastroenterol. 2012 Aug 16;12:111.

17.

PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C.

Petta S, Vanni E, Bugianesi E, Rosso C, Cabibi D, Cammà C, Di Marco V, Eslam M, Grimaudo S, Macaluso FS, McLeod D, Pipitone RM, Abate ML, Smedile A, George J, Craxì A.

Aliment Pharmacol Ther. 2015 May;41(10):939-48. doi: 10.1111/apt.13169. Epub 2015 Mar 20.

18.

I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.

Park JH, Cho B, Kwon H, Prilutsky D, Yun JM, Choi HC, Hwang KB, Lee IH, Kim JI, Kong SW.

Liver Int. 2015 Dec;35(12):2537-46. doi: 10.1111/liv.12909. Epub 2015 Jul 23.

PMID:
26148225
19.

Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease.

Trépo E, Gustot T, Degré D, Lemmers A, Verset L, Demetter P, Ouziel R, Quertinmont E, Vercruysse V, Amininejad L, Deltenre P, Le Moine O, Devière J, Franchimont D, Moreno C.

J Hepatol. 2011 Oct;55(4):906-12. doi: 10.1016/j.jhep.2011.01.028. Epub 2011 Feb 18.

PMID:
21334404
20.

Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity.

Guichelaar MM, Gawrieh S, Olivier M, Viker K, Krishnan A, Sanderson S, Malinchoc M, Watt KD, Swain JM, Sarr M, Charlton MR.

Obesity (Silver Spring). 2013 Sep;21(9):1935-41. doi: 10.1002/oby.20327. Epub 2013 May 29.

Supplemental Content

Support Center